|
Andrew Dorr, M.D. is a medical oncologist with extensive experience developing clinical programs for biopharmaceutical companies. He has over 20 years of experience in drug development, regulatory compliance and executive oversight for pharmaceutical companies. He served as Chief Operating Officer at Salmedix, Inc., and Chief Medical Officer and Vice President of Drug Development at Isis Pharmaceuticals, Inc. Previously, he was an Associate Professor of Medicine at Indiana University School of Medicine and worked in clinical and medical research roles with Eli Lilly and Company. Dr. Dorr also served for seven years as a Senior Investigator with the Cancer Therapy Evaluation Program at the National Cancer Institute's Division of Cancer Treatment. He received his medical degree from the University of North Carolina in Chapel Hill, North Carolina and is a member of American Society of Clinical Oncology and American Association for Cancer Research. | 